Obesity has become the most economically consequential condition affecting employer health plans.

GLP-1 drugs have ignited unprecedented demand-reshaping benefit design, pharmacy spend, wellness ecosystems, and expectations for rapid weight loss. Yet the employer challenge is no longer just “Should we cover GLP-1s?” It is now “How do we manage obesity ( the associated comorbidities ) holistically, sustainably, and cost effectively?” This strategic framework presents a new, integrated view combining food-as-medicine, precision biology, and targeted pharmacotherapy.  Read More about Digbi Health’s research on rethinking obesity care.